Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials

What Was Tested

Researchers studied Leuprolide in this randomized controlled trial publication.

The current trial evaluated 2 common therapies for patients with advanced prostate cancer, docetaxel and hormonal therapy (HT), in the surgical adjuvant setting.

Who Took Part

According to the abstract, 2 patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults, men only.

TAX-3501 was a randomized, phase 3, adjuvant study post-radical prostatectomy (RP) in high-risk patients with prostate cancer (n=228) comparing 18 months of HT with (CHT) without docetaxel chemotherapy either immediately (I) or deferred (D).

The authors also assessed the accuracy of the nomogram and analyzed testosterone recovery in 108 patients treated with HT who had at least 1 posttreatment testosterone value.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Leuprolide and who got the comparison, which limits bias.

Progression-free survival (PFS), including prostate-specific antigen disease recurrence, was the primary endpoint.

What Was Measured

The current trial evaluated 2 common therapies for patients with advanced prostate cancer, docetaxel and hormonal therapy (HT), in the surgical adjuvant setting.

PubMed files the paper under topics including Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Disease Progression, Docetaxel, International Agencies, Leuprolide and Neoplasm Staging.

The authors tagged it with the keywords adjuvant therapy, prostate cancer and testosterone recovery.

What This Means in Plain Language

The paper is a randomized study of Leuprolide in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (Cancer), a journal based in United States.

More context: the Leuprolide compound page, all human trials.